INTRODUCTION
Among the rickettsioses, Q fever has specific pathological and clinical features which do not allow it to be reviewed in comparison with other rickettsioses. Arthropod-borne rickettsioses comprise three distinct disease groups: spotted fever rickettsioses, typhus, and scrub typhus. Among the spotted fever rickettsioses, Rocky Mountain spotted fever (RMSF), Mediterranean spotted fever (MSF), and tick typhus of the eastern hemisphere have been widely studied. In this report we review the in vitro and in vivo efficacies of antibiotic treatments for arthropod-borne rickettsioses.
Since 1948, when the first cases of RMSF were treated with chloramphenicol (32), these diseases have been curable. Despite this therapeutic evolution, RMSF lethality remains high (4%) (13) , as does MSF lethality in several countries (44) . In Japan, it was suggested that the apparent increasing incidence of rickettsiosis during the 1970s was related to a change in empiric antibiotic therapy for unexplained febrile illness (56) . The ineffective beta-lactams were prescribed, despite the existence of effective drugs, i.e., chloramphenicol and tetracycline. Since spotless fever has been described both in patients with RMSF (33, 58) and in patients with MSF (8) , rickettsioses may present early as nonspecific febrile illnesses; these illnesses were previously undiagnosed and were cured by empiric antibiotic therapy, but they developed when beta-lactams began to be used. The delay in administration of an effective antibiotic leads to enhanced mortality (44, 46, 63) . The recent therapeutic use of new quinolone compounds and new macrolides that are active against rickettsiosis may be of importance. Another specific problem is the treatment of pregnant women and young children, for whom tetracyclines are toxic, and the use of chloramphenicol exposes these patients to the risk of aplasia. The cost of treatment is of importance in developing countries, and the prescription of new compounds increases this cost. Ultimately, the treatment duration is still questioned, and shortened treatment durations have been proposed. The investigator who advocates changes in accepted treatment regimens for rickettsial diseases should critically evaluate some important issues. First, testing of the in vitro efficacy of a new drug on representative organisms is critical. The availability of a larger number of strains allows the evaluation of heterogeneous susceptibilities. The in vitro data should not be directly extrapolated to treatment regimens for use in humans. (23), who described the reduction of plaque formation by antibiotic compounds. A microplate colorimetric assay has been developed which is more convenient and which provides results comparable to those of the plaque assay (41) . The only two strains tested were Rickettsia rickettsii (Sheila Smith) and Rickettsia conorii (Moroccan strain). The results of these studies are given in Table 1 . The cutoff point of the optimal efficient dilution factor has not been fully resolved because of the intracellular location of rickettsiae. From these data, it can be concluded that tetracycline, doxycycline, chloramphenicol, and rifampin are effective against R. rickettsii and R. conorii. Among the macrolide antibiotics, erythromycin has MICs of 4 to 8 ,ug/ml; spiramycin is not effective; josamycin, roxithromycin, and pristinamycin have MICs of 1 to 2 pLg/ml. Among the quinolones, ciprofloxacin, pefloxacin, ofloxacin, and sparfloxacin appear to be effective, but nalidixic acid is not (36) . Beta-lactams, aminoglycosides, and trimethoprimsulfamethoxazole are not active.
(ii) Embryonated eggs. The embryonated egg model has been widely used. Inoculation of viable rickettsiae into the yolk sac results in the death of the embryo within a few days. When the antibiotic compound is injected after the infecting inoculum is given, the difference in the mean survival times of the embryos is evaluated. The antibiotic efficacy against the rickettsial strain is determined by survival time. This model is laborious and requires a large number of fertile hen eggs. With this system it is difficult to extrapolate dosages in milligrams per egg to dosages for clinical use. For example, conclusions regarding erythromycin susceptibility differed in the embryonated egg assay, which showed that 125 mg per egg was effective (54) , and with the plaque assay, in which 2 p.g/ml was not effective.
(iii) Animal models. Several laboratory animals are susceptible to rickettsial infections. Intraperitoneal injection of viable rickettsiae is the usual route of inoculation. Reductions in mortality and the duration of fever are taken as measures of antibiotic effectiveness. Chloramphenicol showed some beneficial effects, but these effects were much less striking than those obtained in embryonated eggs (49) , whereas chlortetracycline was effective (62) . Recent studies in dogs infected with R. rickettsii showed that doxycycline, chloramphenicol, and enrofloxacin, a quinolone compound, were equally effective (7). Typhus group. (i) Cell culture models. The same models described above for spotted fever group rickettsiae were applied to typhus group rickettsiae (61) . All studies confirmed the efficacy of chloramphenicol, tetracycline, doxycycline, minocycline, and rifampin, with MICs ranging from 0.008 to 1 p.g/ml. Among the macrolide compounds, only erythromycin was tested, and it was found to be effective. An exception was the Rickettsia prowazekii Madrid E strain, which was resistant (20) . Nalidixic acid produced partial inhibition of plaque formation and new quinolones were moderately active (25) . Beta-lactams and aminoglycosides were not effective. A few studies showed that high concentrations of penicillin G (20 to 100 mg/liter) were marginally active (25, 60) .
(ii) Embryonated eggs. The embryonated egg model was used in older studies (18) . Those results compare favorably with tests done by using cell culture systems (Table 2) ; i.e., oxytetracycline, doxycycline, and erythromycin were effective, but the beta-lactams and aminoglycosides were not. Discrepancies, however, were noted for chloramphenicol, which was not effective in the embryonated egg model.
(i1l) Animal models. Boese and colleagues (6) and Klimchuk (19) treated experimentally infected body lice with rifampin and doxycycline. Otherwise, the same animal systems described above for the spotted fevers were used to evaluate typhus group rickettsiae. Chlortetracycline was effective in animals, but penicillin G was not. Chloramphenicol was said to be effective if it was given early after inoculation with a low inoculum. Recently available compounds have not been tested in animal models.
Scrub typhus. (i) Cell culture models. In tissue cell cultures, the three major serotypes of Rickettsia tsutsugamushi were susceptible to tetracycline, demethylchlortetracycline, doxycycline, minocycline, chloramphenicol, and rifampin. New quinolones were only moderately active (25) . Betalactams and nalidixic acid were inactive (25, 60) (Table 3) . Further study (57) showed that the susceptibility patterns of recent isolates did not differ from those determined with prototype strains. In interpreting the results, one must recall that the cell wall of R. tsutsugamushi differs from those of other rickettsiae.
(ii) Embryonated egg model. In the embryonated egg model, oxytetracycline (Terramycin; Pfizer), aureomycin, and chloramphenicol were rickettsiostatic, but penicillin and streptomycin were found to be inactive (18) .
(iii) Animal models. A recent study with experimentally infected mice showed that chloramphenicol and ciprofloxacin are effective in treating scrub typhus, whereas gentamicin is not (22 Gudiol et al. (14) was randomized by using ciprofloxacin versus doxycycline. Four oral doses of 500 mg of ciprofloxacin given every 12 h cured all patients. However, apyrexia was more rapid with doxycycline. Ruiz-Beltran and HerreroHerrero (45) found that ciprofloxacin at doses of 750 mg every 12 h and tetracyclines and doxycycline at doses of 100 mg every 12 h were equally effective (45) . Hence, ciprofloxacin could be an alternative to tetracycline for the treatment of MSF. Ofloxacin (200 mg every 12 h) was successfully used by Raoult et The patients failed to respond to treatment. However, 31 patients treated with 200 mg every 12 h responded to treatment but experienced a longer delay than that experienced in patients given ciprofloxacin or doxycycline. The investigators (45) suggested that 400 mg given every 12 h should provide better results.
Two macrolide antibiotics, erythromycin and josamycin, have been evaluated. We have completed a computerized surveillance program of MSF which now includes 455 patients (11) . Among these patients, 435 received antibiotic treatment. Erythromycin was prescribed in 35 patients and failed in 6 patients; co-trimoxazole was used in four patients with three failures. Erythromycin was prescribed by Miller and Gear (24) for patients with South African tick fever; two of these patients failed to respond to the treatment. Munoz Espin et al. (27) randomly compared erythromycin with doxycycline in children and observed failures and delayed apyrexia with erythromycin. The same team recently compared josamycin with doxycycline and concluded that josamycin is effective (3). We successfully treated two pregnant women by using 3 g ofjosamycin per day for 8 days (34) . These results, which are regarded as preliminary, suggest that josamycin could eventually cure MSF. This is of potential importance, because an innocuous antibiotic regimen for children and pregnant women is needed.
On the basis of a low in vitro MIC, rifampin showed good potential as an antirickettsial drug. However, in a preliminary study which compared rifampin with doxycycline, Bella et al. (2) showed that rifampin failed to cure children with MSF. That study, if confirmed, is the first example of a discrepancy between in vitro and in vivo data for MSF. The in vivo inefficacy of co-trimoxazole has been reported recently by Ruiz-Beltran and Herrero-Herrero based on study in 10 patients (45) .
The duration of antibiotic treatment is unclear. (16, 17, 21, 31) , particularly for use in developing countries, where drugs are scarce. Overall, single-dose doxycycline therapy appears to be slightly more effective than chloramphenicol; this includes therapy for the prevention of death. However, some uncharacterized febrile relapses were observed. A potential difficulty associated with single-dose doxycycline is its lack of efficacy against typhoid fever mistaken for typhus in developing countries. There are two reports of successful treatment of typhus with ciprofloxacin without relapses (12, 55) . Co-trimoxazole is reported to be less effective than doxycycline in treating epidemic typhus (16) .
Scrub typhus. There is no effective vaccine for scrub typhus, which causes high mortality and morbidity in nonimmune populations occupationally exposed in endemic regions. This has led to several chemoprophylaxis trials. Chloramphenicol was not satisfactory therapy, since it did not prevent relapses when administration was stopped (51, 52) . Doxycycline, 200 mg once a week, was effective (28) . As for treatment, chloramphenicol and oxytetracycline were the recommended drugs. Tetracyclines were proved to be more effective than chloramphenicol (1, 52) . Successful treatment was achieved by using a 24-h course of doxycycline (9); however, comparative blind studies indicated that single-dose or two-dose doxycycline is associated with failure and febrile recrudescence (29) . Regardless of the antibiotic regimen (chloramphenicol, tetracycline, or doxycycline), the necessity of retreatment in patients who received therapy less than 5 days after the onset of symptoms was 13% and was 0% for patients whose therapy started after 5 or more days after the onset of illness (29, 51, 52) . Ciprofloxacin was successfully used to treat one patient with scrub typhus (12) . CONCLUSION New evidence is rapidly accumulating regarding the therapeutic effects of antibiotics against rickettsioses. New fluoroquinolones (i.e., ciprofloxacin, pefloxacin, ofloxacin, and sparfloxacin) are effective against rickettsiae of the spotted fever group. Clinical data on RMSF are lacking. Ciprofloxacin showed effectiveness against one case of scrub typhus. Among the macrolide antibiotics, josamycin and roxythromycin, when they are tested in vitro, are effective against rickettsiae of the spotted fever group. Patients with scrub typhus, murine typhus, and MSF have been successfully treated with quinolones. Single-day therapy with doxycycline avoids toxicity and is effective for the treatment of adults and children with MSF. Children and pregnant women could be treated with josamycin for 5 days. The spectrum of available antibiotics for the treatment of rickettsiosis is expanding. Evaluation of these new compounds may allow them to be used as empiric treatment for unexplained febrile illnesses in which rickettsiae could be the etiological agents.
